Amy J Sehnert

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 16

Top Topics

Left Ventricular

Hypertrophic Cardiomyopathy

Psychometric Properties

Top Venues

Journal of the American Heart Association

Circulation. Cardiovascular imaging

CPT: pharmacometrics & systems pharmacology

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Journal of the American Heart Association 13 (8) (2024)
Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Journal of the American Heart Association 13 (8) (2024)
Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Journal of the American Heart Association (2024)
Anjali Tiku Owens, Milind Y Desai, Matthew T Wheeler, Anna Rodonski, Samira M Garonzik, Amy J Sehnert, Sara Saberi
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response. Journal of the American Heart Association 13 (17) (2024)
Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Journal of the American Heart Association 13 (8) (2024)
Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Journal of the American Heart Association 13 (8) (2024)
Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Journal of the American Heart Association 13 (8) (2024)
Milind Y Desai, Yuichiro Okushi, Andrew Gaballa, Qiuqing Wang, Jeffrey B Geske, Anjali Tiku Owens, Sara Saberi, Andrew Wang, Paul C Cremer, Mark V Sherrid, Neal K Lakdawala, Albree Tower-Rader, David Fermin, Srihari S Naidu, Kathy L Lampl, Amy J Sehnert, Steven E Nissen, Zoran B Popovic, null null
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial. Circulation. Cardiovascular imaging (2024)
Anjali Tiku Owens, Milind Y Desai, Matthew T Wheeler, Anna Rodonski, Samira M Garonzik, Amy J Sehnert, Sara Saberi
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response. Journal of the American Heart Association (2024)
Samira M Garonzik, David H Salinger, Maria Palmisano, Amy J Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D Seroogy, Daniel D Gretler, Amit Roy, Vidya Perera
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy. CPT: pharmacometrics & systems pharmacology (2024)
Peter Chang, Vidya Perera, David H Salinger, Samira M Garonzik, Neelima Thanneer, Hyunmoon Back, Julie D Seroogy, Daniel D Gretler, Amy J Sehnert, Maria Palmisano, Amit Roy
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration. CPT: pharmacometrics & systems pharmacology (2024)
Sharon Cresci, Richard G Bach, Sara Saberi, Anjali Tiku Owens, John A Spertus, Sheila M Hegde, Neal K Lakdawala, Ester Kim Nilles, Daniel M Wojdyla, Amy J Sehnert, Andrew Wang
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation (2023)
Matthew Reaney, Prithvi Addepalli, Veleka Allen, John A Spertus, Chantal Dolan, Amy J Sehnert, Jennifer T Fine
Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial. PharmacoEconomics - open 6 (4) (2022)
Milind Y Desai, Anjali Tiku Owens, Jeffrey B Geske, Kathy Wolski, Sara Saberi, Andrew Wang, Mark V Sherrid, Paul C Cremer, Srihari S Naidu, Nicholas G Smedira, Hartzell V Schaff, Ellen McErlean, Christina Sewell, Aarthi Balasubramanyam, Kathy Lampl, Amy J Sehnert, Steven E Nissen
Dose-Blinded Myosin Inhibition in Patients with Obstructive HCM Referred for Septal Reduction Therapy: Outcomes Through 32-Weeks. Circulation (2022)
Paul C Cremer, Jeffrey B Geske, Anjali Tiku Owens, Wael A Jaber, Serge C Harb, Sara Saberi, Andrew Wang, Mark V Sherrid, Srihari S Naidu, Hartzell Schaff, Nicholas G Smedira, Qiuqing Wang, Kathy Wolski, Kathy L Lampl, Amy J Sehnert, Steven E Nissen, Milind Y Desai
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study. Circulation. Cardiovascular imaging (2022)
Matthew Reaney, Veleka Allen, Amy J Sehnert, Liang Fang, Albert A Hagège, Srihari S Naidu, Iacopo Olivotto
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument. PharmacoEconomics - open 6 (4) (2022)